Lv7
5000 积分 2021-04-25 加入
Late Recurrence of Completely Resected Stage I-IIIA Lung Adenocarcinoma
15小时前
已完结
Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC
13天前
已完结
A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel
18天前
已完结
Low avidity T cells drive endogenous tumor immunity in mice and humans
1个月前
已完结
Genomic mechanisms of transformation from chronic obstructive pulmonary disease to lung cancer
1个月前
已完结
Mechanistic links between COPD and lung cancer
1个月前
已完结
Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights
2个月前
已完结
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
3个月前
已完结
PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
3个月前
已完结
143P Efficacy and safety of aumolertinib (AUM) with radiotherapy versus concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III EGFR-mutant NSCLC: A multicenter, randomized, open-label phase III study (ADVANCE)
3个月前
已完结
皖公网安备34019202002308
